.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC02_Basiliximab.Basiliximab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC02_Basiliximab.Basiliximab| name: | Basiliximab |
| ATC code: | L04AC02 | route: | intravenous |
| n-compartments | 2 |
Basiliximab is a chimeric monoclonal antibody that acts as an interleukin-2 (IL-2) receptor antagonist. It is primarily used for the prophylaxis of acute organ rejection in patients undergoing renal transplantation, in combination with other immunosuppressive agents. Basiliximab is currently approved and in use for this indication.
Pharmacokinetic parameters reported for adult renal transplant recipients after intravenous administration, as summarized in multiple studies.
Podichetty, JT, et al., & Kiel, PJ (2020). Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine. Pharmacotherapy 40(1) 26–32. DOI:10.1002/phar.2347 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31742732
Kovarik, JM, et al., & Schmidt, AG (1999). Screening for basiliximab exposure-response relationships in renal allotransplantation. Clinical transplantation 13(1 Pt 1) 32–38. DOI:10.1034/j.1399-0012.1999.t01-2-130105.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/10081632
Offner, G, et al., & Hall, M (2002). A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation 74(7) 961–966. DOI:10.1097/00007890-200210150-00010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12394837